

# General Meeting Shareholder Update

Michael Winlo - MD & CEO


ASX:EMD

myriad data.  
individual care.


## Disclaimer and notices

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.


This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



Emyria creates **treatments**  
for **large, under-served populations** using our  
**proprietary clinical evidence**



# Emyria positioned to rapidly & repeatedly develop new treatments



Emyria's Digital Health Platform

- **TGA-registered** remote monitoring solution
- Incorporates **contactless vital sign capture**
- **Clinical-trial-grade evidence**

Emyria

Care



6 sites in Australia

+ 1 clinical partner in UK

3,500+  
patients and  
counting...



# Emyria data is the brain of our company

Emyria

Data

**2.6M**  
unique  
data  
points

An intelligent  
model for care  
& drug design

**2-96** years  
age range of patients

**56%**  
female patients

**44**  
unique primary indications

**54%**  
patients presenting with symptoms  
of moderate to severe **anxiety**

**53%**  
patients presenting with symptoms  
of moderate to severe **depression**

**7.12**  
average **concomitant medications**  
per patient at initial visit

**0-600**mg  
range of **CBD** prescribed doses  
are carefully titrated for each  
patient which gives Emyria unique  
dose response insights

**0-197**mg  
range of **THC** prescribed doses  
are carefully titrated for each  
patient which gives Emyria unique  
dose response insights


**35%**  
patients experiencing an  
**adverse event**

Data summary as of 01 DEC 2020

# Board with deep clinical and commercial expertise

Key Person	Role
	<p><b>Dr Stewart Washer</b> <b>Chairman &amp; Founder</b></p> <p><b>Cynata</b> (ASX:CYP) – stem cells <b>Orthocell</b> (ASX:OCC) – regenerative medicine <b>Botanix</b> (ASX:BOT) – CBD (synthetic)</p> 
	<p><b>Dr Michael Winlo</b> <b>Managing Director</b></p> <p><b>Medical doctor</b> Director at <b>Linear Clinical</b> Health Lead at <b>Palantir</b> MBA from <b>Stanford University</b></p> 
	<p><b>Dr Alistair Vickery</b> <b>Medical Director</b></p> <p>Specialist <b>general practitioner</b> Chair of <b>Black Swan Health</b>, - mental health Associate <b>Professor of Primary Health Care</b></p> 
	<p><b>Matt Callahan</b> <b>NED &amp; Founder</b></p> <p>Founder <b>Botanix</b> (ASX:BOT), Founder <b>Orthocell</b> (ASX:OCC) 4 products through <b>FDA approval</b>. More than 20 years' <b>legal and IP experience</b></p> 
	<p><b>Professor Sir John Tooke</b> <b>Independent NED</b></p> <p><b>Knighted</b> in the UK for Services to Medicine Senior Independent Director, <b>BUPA Chile</b> Head of Medical Sciences at <b>UCL</b> Review board of <b>Google DeepMind</b> Immediate past <b>President Academy of Medical Sciences</b></p> 

# Recently appointed Key Advisors


Key Person	Role
	<p data-bbox="669 714 1402 757"><b>Dr Karen Smith</b> M.D., Ph.D., M.B.A., L.L.M</p> <p data-bbox="669 799 1279 846"><b>Chair of Strategic Advisory</b></p> <ul data-bbox="1426 568 2409 1065" style="list-style-type: none"> <li>• Experienced <b>pharmaceutical expert</b></li> <li>• <b>Multiple Directorships</b> with innovative pharmaceutical companies</li> <li>• Ex-<b>Chief Medical Officer and Global Head of R&amp;D at Jazz Pharmaceuticals</b></li> <li>• Overseen more than <b>100 clinical trials and 20 regulatory approvals</b></li> <li>• Appointment boosts Emyria’s global clinical trial and regulatory approval expertise to accelerate drug registration</li> <li>• Appointment to support innovation across Emyria’s drug development programs, clinical studies and evidence-generating care model</li> </ul> 
	<p data-bbox="669 1339 1236 1386"><b>Dr Richard Magtengaard</b></p> <p data-bbox="669 1427 1202 1474"><b>Consultant Psychiatrist</b></p> <ul data-bbox="1426 1127 2409 1699" style="list-style-type: none"> <li>• <b>Consultant Psychiatrist</b> and retired <b>Naval Officer</b></li> <li>• Current <b>Director of Military Trauma Recovery</b> Programme for sustained physical and psychological traumas</li> <li>• active member of the <b>Australasian Military Medical Association (AMMA)</b> and has developed lasting affiliations with <b>ADF Joint Health Command (JHC)</b>, <b>Returned Services League WA (RSLWA)</b>, <b>St John Ambulance (SJA)</b>, <b>West Australian Police (WAPOL)</b>, <b>Department of Fire and Emergency Services (DFES)</b>, <b>Australian Federal Police (AFP)</b> and numerous other Ex-Service Organisations (ESOs)</li> <li>• Appointment boosts Emyria’s clinical expertise in mental health care</li> </ul> 

# Corporate Structure

Key Metrics	Value
Ordinary shares	225.5
Last close (04 March 2021)	A\$0.165
<b>Market Capitalisation (Date)</b>	<b>A\$37.2m</b>
Cash (31 December 2020)	A\$4.5m
Debt (31 December 2020)	-
<b>Enterprise value</b>	<b>A\$33.2m</b>
Options (ex. price \$0.45, exp. 2023)	18.35m
Options (ex. price \$0.114, exp. 2023/2024 )	12.50m
Options (ex. price \$0.20, exp. 2022)	10.71m

Share trades last 6 months






# Research & development pipeline




# Emyria's pipeline targets large, under-served markets



**+40** other indications

Cannabinoid
  Psychedelic therapy
  In planning
  Where we are now

\* Under Australia's Therapeutic Goods Administration (TGA), psychedelic medications such as psilocybin and MDMA are currently Schedule 9 of the Uniform Scheduling of Medicines and Poisons (which deals with Prohibited Substances). They are only available via approved research trials that include oversight by an institutional research ethics committee and careful monitoring and reporting of efficacy and safety outcomes. This work is with partner Mind Medicine Australia.



# **An ethical and efficient framework to develop and register novel drugs**

# Evidence, guiding every move

- At Emyria, we offer personalised care via Emerald Clinics (**Emyria Care**); underpinned by clear evidence protocols and technology infrastructure (**Emyria Data**); to support novel drug development in compliance with key regulators (i.e. TGA, FDA).
- This framework is efficient, safe and effective for supporting our patients, whilst we simultaneously develop and pursue registration for novel drugs (**Emyria Treatments**).
- Our goal is to put evidence first, always. That means leading the market with sophisticated **real world evidence** (RWE) generating systems too, which is a core point of difference for our Company.


# A “typical” EMD patient

I have a complex and chronic disease.

My current treatments are not effective. I still have health goals that aren't being met.


I don't want to get “high”.

I've been told “nothing else to try right now.”




I want “care” not “access”. I want to get better.

# People like Bob deserve personalised care, backed by reliable clinical evidence



- Emerald Clinics' patients have often exhausted multiple avenues of conventional treatment.
- Typically, they have been told ***“there’s nothing else”***
- Through our clinics, we provide a monitored environment to try novel drugs, with the right clinical evidence systems and support teams in place
- Our patients receive personalised care and an opportunity to contribute to, and leverage, Emyria’s growing body of aggregate clinical data and insights.



# Case Study - Bob



- Vietnam Veteran | injured by fall in 1969 | multiple fractures
- Chronic back pain | peripheral neuropathy from Agent Orange | PTSD
- **At initial visit:** oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
- **Now:** Stable at 15mg 1:1 THC/CBD | **ceased all opiates**, pregabalin and PEA




## Scores

## Initial assessment

## Visit 5

<b>BPI Pain severity score</b>	<b>5.0</b>	<b>1.75</b>
<b>BPI Pain interference score</b>	<b>5.29</b>	<b>0.86</b>
<b>Visual analogue scale</b>	<b>5.0</b>	<b>1.0</b>
<b>Insomnia severity score</b>	<b>12.0</b>	<b>1.0</b>
<b>DASS 42 Depression</b>	<b>14</b>	<b>4</b>
<b>DASS 42 Anxiety</b>	<b>16</b>	<b>2</b>
<b>DASS 42 Stress</b>	<b>16</b>	<b>12</b>



**Registering novel drugs is a noble and profitable pursuit**

# Medicinal cannabis access in Australia

**52 medicinal cannabis products available in Australia**

**1**

**Medicinal cannabis** products are “unregistered” meaning, they are only available to patients via Special Access Schemes, Authorised Prescriber programs or clinical trials\*

\*  **only 1 product is registered & available via routine prescription** (Epidyolex - GW Pharma) and only for **rare forms of epilepsy** with an estimated prevalence of 1 in 20k-40k

# Recent deals | Jazz acquires GW Pharma (\$7.2B USD)



## **Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader**

February 3, 2021

**Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster**

**Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth**

**Anticipated to be accretive in first full year of combined operations and substantially accretive thereafter**


**Conference call today at 8:30 AM ET**

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for \$220.00 per American Depositary Share (ADS), in the form of \$200.00 in cash and \$20.00 in Jazz ordinary shares, for a total consideration of \$7.2 billion, or \$6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.

Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.

*\* Recent Chair of Emyria's Strategic Advisory is Dr Karen Smith, ex-CMO and Global Head of R&D at Jazz Pharmaceuticals*



# Prescription counts by select drug groupings in Australia in 12 months



\* 0.08% of registered prescriptions shown to the right



EMD patient



Large under-served patient market



Mental Health

**20.1% of all Australians**

Psychological distress is growing in incidence

Major growing health concern



IBS

**11% of all Australians**

No targeted drug treatment





Future indications

**44+ indications**

**Emyria Data** provides unique dose-response insights

**Emyria Care** has increasing treatment options



**Emyria is poised for growth**


# Within 12 months we have...



- Over **3,500 patients** with unmet needs
- **7 clinic locations** Emerald Clinics
- **Specialist advisors & GCP-trained GPs**
- **Over 400 referring clinicians**



- Launched **2 drug development programs**:
- **EMD-003** (schedule 3 medicine for psychological distress)
- **EMD-004** (cannabinoid for IBS)



- Over **2.6M validated data points**
- \$1M of data deals inc. with **Canopy Growth Corp**



- Multiple **PhD-trained data analysts**
- Informing **strategic trial design**
- **Patents** already filed




- **TGA registered** remote monitoring systems
- **Major WA Health grant award** (\$880k) for remote monitoring of vital signs and mental health




- **UK** clinical partner - Sapphire Medical (London)
- **USA** strategic partner - Mt Sinai (New York)
- Partnership with Mind Medicine **Australia** to develop **psychedelic-assisted therapy models**

# Timeline (to date)




# Emyria positioned to rapidly & repeatedly develop new treatments



Emyria's Digital Health Platform

- Obtain further **TGA registrations**
- Incorporate best-in-class vital sign technology to develop **digital biomarkers**
- Work with **partners (eg Mt Sinai)** to extend platform capability



**myriad data.**  
**individual care.**

## Contact Information

Michael Winlo: [mwinlo@emyria.com](mailto:mwinlo@emyria.com)

Investors: [investors@emyria.com](mailto:investors@emyria.com)

Media: [media@emyria.com](mailto:media@emyria.com)

General: [info@emyria.com](mailto:info@emyria.com)

ASX:EMD